Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology
January 07, 2021 07:00 ET
|
Gradalis, Inc.
The VITAL study, published in The Lancet Oncology, demonstrates that Vigil first-line maintenance treatment resulted in improved RFS in BRCA1/2-wt ovarian cancer when compared to placebo.Importantly...
Global $136.7 Billion Oncology Market to 2025
October 30, 2020 03:13 ET
|
Research and Markets
Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Oncology Market - Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. Oncology Market size was valued at $136.7...
THE NATIONAL OVARIAN CANCER COALITION TO HOST ITS ANNUAL TOGETHER IN TEAL® - NO BOUNDARIES NATIONAL BROADCAST CELEBRATION DURING SEPTEMBER AWARENESS MONTH ON SATURDAY, SEPTEMBER 26, 2020
August 28, 2020 11:00 ET
|
National Ovarian Cancer Coalition
Dallas, Texas, Aug. 28, 2020 (GLOBE NEWSWIRE) -- DALLAS, TX August 28, 2020 —September is National Ovarian Cancer Awareness Month. The National Ovarian Cancer Coalition (NOCC) is tirelessly working...
Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer
March 30, 2020 08:00 ET
|
Aravive, Inc.
Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abstracts Published on Website of...
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
February 18, 2020 08:00 ET
|
Aravive, Inc.
Dose escalation of AVB-500 to 20mg/kg dose follows positive recommendation by independent Data Monitoring Committee review Plan to initiate Phase 2/3 study in Platinum Resistant Ovarian Cancer by...
Predictive Oncology Featured in Broadcast Evaluating Targeted Cancer Therapies, Higher Survival Rates
November 07, 2019 08:30 ET
|
Predictive Oncology
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) announces the availability of a broadcast titled, “New Hope in the Battle Against Ovarian...
Predictive Oncology Featured in Publication Discussing the Impact of Artificial Intelligence on Cancer Treatment
November 06, 2019 08:30 ET
|
Predictive Oncology
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology (NASDAQ: POAI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted...
Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer
November 05, 2019 08:00 ET
|
Celsion CORP
GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --...
Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
October 29, 2019 19:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ADELAIDE, Australia, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) has today announced that Telix and AusHealth have entered into a collaboration...
Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 22, 2019 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...